Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies.

Not yet recruiting

• Conditions: Bone Disorder

• Registration Number: NCT06444503
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

The aim of this project is to set up a biological and clinical collection of patients with progressive bone, calcium and growth plate pathologies.

This collection will provide a better understanding of the mechanisms involved in growth plate and bone damage in these diseases and identify factors predictive of progression and new therapeutic targets.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-05
• Study First Submitted: 2024-05-30
• Study First Submitted QC: 2024-05-30
• Last Update Submitted: 2024-05-30
• Study First Posted: 2024-06-05
• Last Update Posted: 2024-06-05
• Study Start: 2024-08
• Primary Completion: 2034-08
• Study Completion: 2034-08

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• Children (from birth) with growth plate or bone pathology
• Patients affiliated to or benefiting from a social security scheme
• Patients able to receive information about the study and to understand the information form in order to participate in the study. This implies :
• mastery of the French language
• Not being subject to a restriction of rights by the judicial authorities
• Patients or legal representatives having given their consent to participate in the study (expression of non-opposition).

Exclusion Criteria

• Patients under legal protection (guardianship, curatorship or safeguard of justice)
• Pregnant or breast-feeding women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Building a collection of biological samples and clinical-biological data from patients presenting bone, calcium and growth plate pathologies	Day 0 and through study completion, an average of 5 years	Blood and urine sampling

Secondary Outcome Measures

Name	Time	Method
Identification of potential markers of disease progression based on new knowledge.	Day 0 and through study completion, an average of 5 years

Trial Locations

Locations (1)

University Toulouse Hospital; 🇫🇷 Toulouse, France